These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 2337121

  • 1. Protamine antibody production in diabetic subjects treated with NPH insulin.
    Ellerhorst JA, Comstock JP, Nell LJ.
    Am J Med Sci; 1990 May; 299(5):298-301. PubMed ID: 2337121
    [Abstract] [Full Text] [Related]

  • 2. Immunologic analysis of anaphylaxis to protamine component in neutral protamine Hagedorn human insulin.
    Dykewicz MS, Kim HW, Orfan N, Yoo TJ, Lieberman P.
    J Allergy Clin Immunol; 1994 Jan; 93(1 Pt 1):117-25. PubMed ID: 8308177
    [Abstract] [Full Text] [Related]

  • 3. Circulating IgG antibody to protamine in patients treated with protamine-insulins.
    Kurtz AB, Gray RS, Markanday S, Nabarro JD.
    Diabetologia; 1983 Oct; 25(4):322-4. PubMed ID: 6196244
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Frequency and specificity of protamine antibodies in diabetic and control subjects.
    Nell LJ, Thomas JW.
    Diabetes; 1988 Feb; 37(2):172-6. PubMed ID: 3292313
    [Abstract] [Full Text] [Related]

  • 6. Increased risk of severe protamine reactions in NPH insulin-dependent diabetics undergoing cardiac catheterization.
    Stewart WJ, McSweeney SM, Kellett MA, Faxon DP, Ryan TJ.
    Circulation; 1984 Nov; 70(5):788-92. PubMed ID: 6488493
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen.
    Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J.
    Clin Ther; 2004 May; 26(5):724-36. PubMed ID: 15220016
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study.
    Rosenstock J, Fonseca V, McGill JB, Riddle M, Hallé JP, Hramiak I, Johnston P, Davis M.
    Diabetologia; 2009 Sep; 52(9):1778-88. PubMed ID: 19526210
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Bovine and human NPH insulins as T cell immunogens.
    Gregory R, Tattersall RB.
    Diabetes Res Clin Pract; 1993 May; 20(2):139-46. PubMed ID: 8375267
    [Abstract] [Full Text] [Related]

  • 17. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
    Hemmingsen B, Metzendorf MI, Richter B.
    Cochrane Database Syst Rev; 2021 Mar 04; 3(3):CD013498. PubMed ID: 33662147
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Association of protamine IgE and IgG antibodies with life-threatening reactions to intravenous protamine.
    Weiss ME, Nyhan D, Peng ZK, Horrow JC, Lowenstein E, Hirshman C, Adkinson NF.
    N Engl J Med; 1989 Apr 06; 320(14):886-92. PubMed ID: 2648147
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.